1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Cutting Through The Confusion On US Biosimilar Interchangeability

Experts Offer Clarity Amid Misunderstandings Over US FDA Designation

 
• By Dave Wallace

Amid ongoing confusion around the US interchangeability designation for biosimilars, Joseph Park and Gillian Woollett of Samsung Bioepis talk to Generics Bulletin about the risks of misinformation, the importance of educational efforts, and how language is shaping certain misunderstandings around biosimilars.

Question mark cards in a jar
Confusion remains over aspects of the US FDA interchangeability designation • Source: Shutterstock

With the first three interchangeability designations having been granted for biosimilars by the US Food and Drug Administration and one of them being an interchangeable Humira (adalimumab) biosimilar, plus multiple adalimumab biosimilars lined up for launch in 2023, the US interchangeability designation is attracting more and more attention among industry stakeholders.

However, with confusion persisting over interchangeability in the US – including the misleading implication that biosimilars without the designation are...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Byooviz US Launch Slated For 2026 As Harrow Touts Immediate Uptake Potential

 
• By Dean Rudge

Harrow is taking aim at launching new partner Samsung Bioepis’ Byooviz biosimilar to Lucentis in 2026.

Richter Sets Launch Timetable for Denosumab and Tocilizumab Biosimilars

 
• By Dean Rudge

Gedeon Richter’s management discussed timelines for two key biosimilars during the firm’s first-half earnings call, while also revealing how the firm’s General Medicines division had suffered setbacks in the three months to June 30.

Lupin Couples Up With Sandoz For Global Lucentis Biosimilar Deal

 
• By Urtė Fultinavičiūtė

Sandoz snatched commercialization rights to Lupin’s ranibizumab biosimilar across multiple global markets, while also taking steps to decarbonize its operations in Europe.

Lupin Launches Generic Version Of Lilly’s Discontinued Glucagon In The US

 
• By Urtė Fultinavičiūtė

Alongside biosimilars, Lupin sees injectable products as one of the key growth drivers in the US, as competition for two of its “material” drugs and proposed tariffs are looming over the firm.

More from Products

Hikma Rides Price Gap as Novo’s Ozempic, Wegovy Costs Climb

 
• By Dean Rudge

Hikma is seeing increased US demand for its generic Victoza (liraglutide) after the end of semaglutide compounding lifted prices for Novo Nordisk’s Ozempic and Wegovy. Meanwhile, the company is not for now pursuing semaglutide generics in the US or EU due to patent protection, but is targeting MENA.

Lupin Launches Generic Version Of Lilly’s Discontinued Glucagon In The US

 
• By Urtė Fultinavičiūtė

Alongside biosimilars, Lupin sees injectable products as one of the key growth drivers in the US, as competition for two of its “material” drugs and proposed tariffs are looming over the firm.

Arizonans To Be Offered Up To 80% Discount On Generic Drugs

 
• By Urtė Fultinavičiūtė

Arizona’s governor Katie Hobbs pointed to Trump’s One Big Beautiful Bill and other federal failures as she signed an executive order to increase access to medications in her state.